logo
Plus   Neg
Share
Email

Argos Therapeutics Inc. (ARGS) Is Climbing On Option Agreement

Argos Therapeutics Inc. (ARGS) announced Tuesday morning that it has entered into an option agreement with Pharmstandard International S.A. and Actigen Limited. The deal gives the company an option to license a group of fully human anti-PD1 monoclonal antibodies and related technology.

Argos Therapeutics gapped up at the open Tuesday and has continued to rise in early trade. Shares are now up 0.70 at $2.40.

For comments and feedback contact: editorial@rttnews.com

Business News

Intraday Alerts

0 Articles
Follow RTT